The VINCENT trial is an open-label, multi-center, phase 2 trial evaluating VEN/AZA as compared to SOC in younger, medically fit patients with treatment-naïve NPM1-mutated AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.